Artesunate Vaginal Inserts for the Treatment of Cervical Intraepithelial Neoplasia (CIN2/3)

This is a phase II double blind, placebo-controlled, randomized study of Artesunate vaginal inserts for the treatment of women who have cervical high grade intraepithelial neoplasia (CIN2/3).

Trial Details

NCT ID
NCT04098744
Phase
PHASE2
Sponsor
Frantz Viral Therapeutics, LLC
Status
RECRUITING
Cancer Type
Cervical Cancer
Interventions
  • Artesunate vaginal insert
  • Placebo vaginal insert
Locations (sample)
  • Fort Myers, Florida, United States|26.62168,-81.84059
  • Ann Arbor, Michigan, United States|42.27756,-83.74088
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Cleveland, Ohio, United States|41.4995,-81.69541
  • Mayfield Heights, Ohio, United States|41.51922,-81.4579

Key Eligibility Criteria

  • Adult females age ≥ 25 years
  • Capable of informed consent
  • Any HPV genotype detectable by DNA test/HPV genotyping
  • Colposcopically-directed, histologically confirmed tissue diagnosis of cervical high grade squamous intraepithelial lesions (CIN2, CIN3, or CIN2/3)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Cervical Cancer Trials on Trialify →